Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 255

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 255
---
)Scenario 1: Considering that the balance in the Trust Account, including accrued interest receivable, is $6,268,825, the contribution under the Backstop Agreement amounts to $3,731,170. At a price of $10 per share, this contribution results in the issuance of 373,117shares. (b)Scenario 2:Considering that the balance in the Trust Account, including accrued interest receivable, is $3,134,413, the contribution under the Backstop Agreement amounts to $6,865,580. At a price of $10 per share, this contribution results in the issuance of 686,558shares. (c)Scenario 3: Considering that there is no balance in the Trust Account due to maximum redemptions, the contribution under the Backstop Agreement amounts to $10,000,000. At a price of $10 per share, this contribution results in the issuance of 1,000,000shares. Share premium resulting from the different combinations of Public shareholders redemptions and contributions under the Backstop Agreement does not differ across the different scenarios. Said Share premium is calculated as the difference between the equity increase and the par value of the issued shares. For more information, see the “Share Premium” section. (2)Reflects the exchange of Sponsor Shares (4,312,500 Class B ordinary shares) for Company Shares, considering the par value of $0.0001 per share, as part of the Business Combination. Therefore, the net adjustment in share capital results from: (i) the elimination of APx’s share capital for $431.25 for consolidation purposes; and (ii) recognition of Company Shares to be issued to Sponsor shareholders for $431.25. Additionally, the adjustment in share premium results from recognition of share premium derived from the issuance of Company Shares to Sponsor shareholders for ($6,171,846) (considering the difference between the book value of the net assets of APx before considering the adjustment described in Note (1), (which amounts to $6,171,846) and the par value of $431.25 of the Company Shares issued). For more detailed information regarding final composition of share premium in each scenario, see section “ Share premium.” Finally, the adjustment in Accumulated deficit includes the elimination of APx’s accumulated deficit of $6,171,846 for consolidation purposes. (3)Represents the preliminary estimated transaction costs to be incurred by OmnigenicsAI for approximately $3.5 million.